345 related articles for article (PubMed ID: 38571961)
1. Toward reproducible tumor organoid culture: focusing on primary liver cancer.
Guo L; Li C; Gong W
Front Immunol; 2024; 15():1290504. PubMed ID: 38571961
[TBL] [Abstract][Full Text] [Related]
2. Next-generation cancer organoids.
LeSavage BL; Suhar RA; Broguiere N; Lutolf MP; Heilshorn SC
Nat Mater; 2022 Feb; 21(2):143-159. PubMed ID: 34385685
[TBL] [Abstract][Full Text] [Related]
3. Standardization of organoid culture in cancer research.
Zhou C; Wu Y; Wang Z; Liu Y; Yu J; Wang W; Chen S; Wu W; Wang J; Qian G; He A
Cancer Med; 2023 Jul; 12(13):14375-14386. PubMed ID: 37081739
[TBL] [Abstract][Full Text] [Related]
4. Deciphering the Tumor Microenvironment of Colorectal Cancer and Guiding Clinical Treatment With Patient-Derived Organoid Technology: Progress and Challenges.
Li J; Liu J; Xia W; Yang H; Sha W; Chen H
Technol Cancer Res Treat; 2024; 23():15330338231221856. PubMed ID: 38225190
[TBL] [Abstract][Full Text] [Related]
5. Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank.
Zhou Z; Cong L; Cong X
Front Oncol; 2021; 11():762184. PubMed ID: 35036354
[TBL] [Abstract][Full Text] [Related]
6. Developing liver organoids from induced pluripotent stem cells (iPSCs): An alternative source of organoid generation for liver cancer research.
Nguyen R; Da Won Bae S; Qiao L; George J
Cancer Lett; 2021 Jun; 508():13-17. PubMed ID: 33771683
[TBL] [Abstract][Full Text] [Related]
7. Progress in patient-derived liver cancer cell models: a step forward for precision medicine.
Zhang Z; Hui L
Acta Biochim Biophys Sin (Shanghai); 2023 Nov; 55(11):1707-1717. PubMed ID: 37766458
[TBL] [Abstract][Full Text] [Related]
8. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology.
Ji S; Feng L; Fu Z; Wu G; Wu Y; Lin Y; Lu D; Song Y; Cui P; Yang Z; Sang C; Song G; Cai S; Li Y; Lin H; Zhang S; Wang X; Qiu S; Zhang X; Hua G; Li J; Zhou J; Dai Z; Wang X; Ding L; Wang P; Gao D; Zhang B; Rodriguez H; Fan J; Clevers H; Zhou H; Sun Y; Gao Q
Sci Transl Med; 2023 Jul; 15(706):eadg3358. PubMed ID: 37494474
[TBL] [Abstract][Full Text] [Related]
9. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.
Broutier L; Mastrogiovanni G; Verstegen MM; Francies HE; Gavarró LM; Bradshaw CR; Allen GE; Arnes-Benito R; Sidorova O; Gaspersz MP; Georgakopoulos N; Koo BK; Dietmann S; Davies SE; Praseedom RK; Lieshout R; IJzermans JNM; Wigmore SJ; Saeb-Parsy K; Garnett MJ; van der Laan LJ; Huch M
Nat Med; 2017 Dec; 23(12):1424-1435. PubMed ID: 29131160
[TBL] [Abstract][Full Text] [Related]
10. Organoid factory: The recent role of the human induced pluripotent stem cells (hiPSCs) in precision medicine.
Novelli G; Spitalieri P; Murdocca M; Centanini E; Sangiuolo F
Front Cell Dev Biol; 2022; 10():1059579. PubMed ID: 36699015
[TBL] [Abstract][Full Text] [Related]
11. Automation of Organoid Cultures: Current Protocols and Applications.
Louey A; Hernández D; Pébay A; Daniszewski M
SLAS Discov; 2021 Oct; 26(9):1138-1147. PubMed ID: 34167363
[TBL] [Abstract][Full Text] [Related]
12. Liver organoids: a promising three-dimensional model for insights and innovations in tumor progression and precision medicine of liver cancer.
Chen Y; Liu Y; Chen S; Zhang L; Rao J; Lu X; Ma Y
Front Immunol; 2023; 14():1180184. PubMed ID: 37334366
[TBL] [Abstract][Full Text] [Related]
13. Drug screening by uniform patient derived colorectal cancer hydro-organoids.
Jung YH; Choi DH; Park K; Lee SB; Kim J; Kim H; Jeong HW; Yang JH; Kim JA; Chung S; Min BS
Biomaterials; 2021 Sep; 276():121004. PubMed ID: 34273688
[TBL] [Abstract][Full Text] [Related]
14. Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy.
Wang J; Chen C; Wang L; Xie M; Ge X; Wu S; He Y; Mou X; Ye C; Sun Y
Front Oncol; 2022; 12():872531. PubMed ID: 35449581
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
Ren X; Chen W; Yang Q; Li X; Xu L
J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
[TBL] [Abstract][Full Text] [Related]
16. Liver Organoids as an In Vitro Model to Study Primary Liver Cancer.
De Siervi S; Turato C
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901961
[TBL] [Abstract][Full Text] [Related]
17. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors.
Cao W; Liu J; Wang L; Li M; Verstegen MMA; Yin Y; Ma B; Chen K; Bolkestein M; Sprengers D; van der Laan LJW; Doukas M; Kwekkeboom J; Smits R; Peppelenbosch MP; Pan Q
Carcinogenesis; 2019 Mar; 40(1):145-154. PubMed ID: 30289434
[TBL] [Abstract][Full Text] [Related]
18. Organoid engineering with microfluidics and biomaterials for liver, lung disease, and cancer modeling.
Kim SK; Kim YH; Park S; Cho SW
Acta Biomater; 2021 Sep; 132():37-51. PubMed ID: 33711526
[TBL] [Abstract][Full Text] [Related]
19. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y
J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147
[TBL] [Abstract][Full Text] [Related]
20. Promises and Challenges of Organoid-Guided Precision Medicine.
Bose S; Clevers H; Shen X
Med; 2021 Sep; 2(9):1011-1026. PubMed ID: 34617071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
